SRR2016957
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.280
- E2F_TARGETS+0.240
- APICAL_SURFACE+0.200
- DNA_REPAIR+0.110
- G2M_CHECKPOINT+0.080
- PANCREAS_BETA_CELLS+0.080
- ALLOGRAFT_REJECTION+0.040
- KRAS_SIGNALING_DN+0.040
- APICAL_JUNCTION+0.020
- HYPOXIA+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- PROTEIN_SECRETION-0.370
- INTERFERON_GAMMA_RESPONSE-0.320
- ANDROGEN_RESPONSE-0.300
- NOTCH_SIGNALING-0.290
- INFLAMMATORY_RESPONSE-0.270
- UV_RESPONSE_DN-0.250
- HEME_METABOLISM-0.240
- ESTROGEN_RESPONSE_EARLY-0.220
- KRAS_SIGNALING_UP-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DBEX7AG2 | Embryonal tumors | — | 0.841 |
| 2 | AUR-AFR5-TTM1-A-1-1-R-A743-41 | — | E | 0.803 |
| 3 | BS_77317DY4 | medulloblastoma | — | 0.801 |
| 4 | BS_VPBMDMQX | medulloblastoma | — | 0.797 |
| 5 | BS_HZRM07TW | medulloblastoma | — | 0.793 |
| 6 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.788 |
| 7 | BS_QT3NZ2YZ | Embryonal tumors | — | 0.785 |
| 8 | R283 | — | — | 0.775 |
| 9 | SRR650150 | — | — | 0.775 |
| 10 | BS_1BWP5MCT | medulloblastoma | — | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |